Status:
UNKNOWN
CART-19 Cells For R/R B-ALL
Lead Sponsor:
Fujian Medical University
Conditions:
Relapsed/Refractory B-cell ALL
Eligibility:
All Genders
1-60 years
Phase:
PHASE2
PHASE3
Brief Summary
There are limited treatment options for relapse/refractory B-cell acute lymphoblastic leukemia(ALL). However,CART-19 cells has emerged as a powerful targeted immunotherapy for highly refractory CD19+ ...
Eligibility Criteria
Inclusion
- Signed written informed consent
- Aged between 1-60 years
- Patients with relapsed/refractory B-cell ALL
- Cardiac: Left ventricular ejection fraction ≥ 50%
- Adequate renal and hepatic function
- Performance status: Karnofsky ≥ 70%
Exclusion
- Pregnant or lactating females.
- Any co-morbidity precluding the administration of CART-19 cells.
Key Trial Info
Start Date :
January 1 2016
Trial Type :
INTERVENTIONAL
End Date :
December 1 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03391739
Start Date
January 1 2016
End Date
December 1 2019
Last Update
January 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fujian Medical University Union Hospital
Fuzhou, Fujian, China, 350001